Currently, the peripherally restricted TPH inhibitor utilized in this study, LX1031, is being investigated clinically for use in treating irritable bowel syndrome (IBS), which is characterized by excess 5-HT (Camilleri, 2010; Brown et al., 2011; Camilleri, 2011). This evidence concerns the gene TPH1 and irritable bowel syndrome.